|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results highlight the need to evaluate the action of glucocorticoid on cancer progression in melanoma, thyroid and colon carcinoma in which B-RAF-V600E is a frequent oncogene, and cancers in which evasion from senescence has been shown.
|
31371485 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results highlight the need to evaluate the action of glucocorticoid on cancer progression in melanoma, thyroid and colon carcinoma in which B-RAF-V600E is a frequent oncogene, and cancers in which evasion from senescence has been shown.
|
31371485 |
2019 |
|
rs121434569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The EGFR resistance mutation T790M should be monitored at cancer progression.
|
31445213 |
2019 |
|
rs1042028
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Accumulating data indicates that the polymorphism rs9282861 (R213H) is responsible for inefficient enzymatic activity and associated with cancer progression.
|
31835852 |
2019 |
|
rs1057519771
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CHMFL-ABL-039 has demonstrated greater efficacies than Imatinib regarding to the anti-proliferation, inhibition of the signaling pathway, arrest of cell cycle progression, induction of apoptosis in vitro and suppression of the tumor progression in vivo in the native and V299L mutated BCR-ABL kinase-driven cells/xenograft models.
|
30894066 |
2019 |
|
rs55958994
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The prostate cancer risk variant rs55958994 regulates multiple gene expression through extreme long-range chromatin interaction to control tumor progression.
|
31328168 |
2019 |
|
rs7121
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this review and meta-analysis, we focus on the synonymous SNP rs7121 (<i>FokI</i>, c.393C>T), which is associated with either tumor progression or prolonged survival in cancer patients (overall hazard ratio = 2.256; p < 0.001).
|
31124412 |
2019 |
|
rs9282861
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Accumulating data indicates that the polymorphism rs9282861 (R213H) is responsible for inefficient enzymatic activity and associated with cancer progression.
|
31835852 |
2019 |
|
rs2273535
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The single nucleotide polymorphism AURKA T91A (rs2273535) (Phe21Ile) has been identified as functional alternator of this kinase, the Ile allele is associated with the occurrence of chromosome segregation errors and tumor progression.
|
28647900 |
2018 |
|
rs2273535
|
|
|
0.020 |
GeneticVariation |
BEFREE |
For esophageal cancer, the AurkA Phe31-Ile polymorphism has previously been associated with tumor progression.
|
29560108 |
2018 |
|
rs3761548
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our study suggests that <i>FOXP3</i> polymorphism rs3761548 is associated with BC susceptibility in the Chinese and may be involved in tumor progression.
|
29731666 |
2018 |
|
rs11672691
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found an association of the aggressive PCa-associated allele G of rs11672691 with elevated transcript levels of two biologically plausible candidate genes, PCAT19 and CEACAM21, implicated in PCa cell growth and tumor progression.
|
30033361 |
2018 |
|
rs121918464
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The E76K GOF mutation is the most common and active SHP2 mutation; however, the pathogenic effects and function of this mutation in CRC tumor progression have not been well characterized.
|
29323748 |
2018 |
|
rs145204276
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The allele del of rs145204276 is associated with a remarkably lower incidence of cancer progression and metastasis.
|
29557411 |
2018 |
|
rs28934578
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Gain-of-function p53 mutants such as p53-R175H form stable aggregates that accumulate in cells and play important roles in cancer progression.
|
29593334 |
2018 |
|
rs562015640
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The E76K GOF mutation is the most common and active SHP2 mutation; however, the pathogenic effects and function of this mutation in CRC tumor progression have not been well characterized.
|
29323748 |
2018 |
|
rs762807774
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4.
|
29679610 |
2018 |
|
rs121913529
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas.
|
28783725 |
2017 |
|
rs121434569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Liquid biopsies (LB) are used routinely in clinical practice in two situations for late stage non-small-cell lung cancer (NSCLC) patients, (i) at the initial diagnosis when looking for activating mutations in EGFR in the absence of analyzable tissue DNA and, (ii) during tumor progression on a tyrosine kinase inhibitor treatment to look for the resistance mutation T790M in EGFR.
|
29069959 |
2017 |
|
rs121434569
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Finally, in the prospective series, SiRe detected 8.7% (4/46) of EGFR mutations at baseline and 42.9% (9/21) of EGFR p.T790M in patients at tumour progression.
|
28170370 |
2017 |
|
rs200863613
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Dysfunction of individual annexin and S100A proteins is associated with cancer progression, metastasis and cancer drug resistance.
|
28068434 |
2017 |
|
rs969139366
|
|
|
0.010 |
GeneticVariation |
BEFREE |
It was worth noting that 31 inhibited GIST-T1 tumor growth (TGI = 81.5%) and even the BaF3-TEL-cKIT-T670I tumor progression (TGI = 41.9%, 1-resistant GISTs) at a dosage of 100 mg/kg/day without exhibiting apparent toxicity.
|
28541695 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
|
26477313 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this phase 2, multicentre, non-randomised, open-label study, we enrolled adult patients (aged ≥18 years) with pretreated metastatic stage IV BRAF(V600E)-mutant NSCLC who had documented tumour progression after at least one previous platinum-based chemotherapy and had had no more than three previous systemic anticancer therapies.
|
27283860 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
|
26477313 |
2016 |